Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NCT ID: NCT06897475
Registry status: Recruiting
Study type: Not specified in the registry data
Phase: Phase 2
Sponsor: Eli Lilly and Company

Overview

ClinicalTrials.gov lists this study as Recruiting.

Enrollment: 200 participants (Estimated).

What is being studied

No interventions are listed in the registry data.

Who may be eligible

Ages: Not specified in the registry data
Sex: Not specified in the registry data
Healthy volunteers accepted: No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Have type 2 diabetes * Have HbA1c ≥7.5% to ≤10.5% at screening * Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening * Have had a stable body weight for the three months prior to screening * On stable treatment dose of one of the following incretins for at least three months prior to screening: * Injectable semaglutide (1 and 2 milligram (mg)) * Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg) Exclusion Criteria: * Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma * Have a prior or planned surgical treatment for obesity * Have any of the following cardiovascular conditions within three months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have used insulin to control blood glucose within the past year (short-term use allowed) * Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening * If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (TZD), they are permitted to participate in the study * Have taken any medications or alternative remedies for weight loss within three months prior to screening

Study locations

60 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: Canada, Germany, Poland, Puerto Rico, United Kingdom, United States

Arizona, United States: 1
California, United States: 1
Florida, United States: 2
Georgia, United States: 4
Idaho, United States: 1
Indiana, United States: 1
New Jersey, United States: 1
New York, United States: 3
North Carolina, United States: 2
Ohio, United States: 1
Oklahoma, United States: 1
Pennsylvania, United States: 1
Texas, United States: 5
Washington, United States: 1

Sample of listed locations

Centricity Research Brampton Endocrinology — Brampton, L6S 0C6, Canada — Site recruitment status not specified in the registry data
Ecogene-21 — Chicoutimi, G7H 7K9, Canada — Site recruitment status not specified in the registry data
Winterberry Research Inc. — Hamilton, L8J 0B6, Canada — Site recruitment status not specified in the registry data
Viacar Recherche Clinique — Longueuil, J4H 4B9, Canada — Site recruitment status not specified in the registry data
G A Research Associates — Moncton, E1G 1A7, Canada — Site recruitment status not specified in the registry data
Bluewater Clinical Research Group Inc. — Sarnia, N7T 4X3, Canada — Site recruitment status not specified in the registry data
Diabetes Heart Research Centre — Toronto, M6G 1M2, Canada — Site recruitment status not specified in the registry data
Maple Leaf Research — Toronto, M5G 1K2, Canada — Site recruitment status not specified in the registry data
Fadia El Boreky Medicine — Waterloo, N2J 1C4, Canada — Site recruitment status not specified in the registry data
InnoDiab Forschung Gmbh — Essen, 45136, Germany — Site recruitment status not specified in the registry data
Gemeinschaftspraxis Dr. Taeschner/Dr. Bonigut — Leipzig, 04249, Germany — Site recruitment status not specified in the registry data
Velocity Clinical Research, Leipzig — Leipzig, 04177, Germany — Site recruitment status not specified in the registry data
Institut für Diabetesforschung GmbH Münster — Münster, 48145, Germany — Site recruitment status not specified in the registry data
RED-Institut GmbH — Oldenburg, 23758, Germany — Site recruitment status not specified in the registry data
Legeartis - Poradnie Specjalistyczne — Bialystok, 15-404, Poland — Site recruitment status not specified in the registry data
Centrum Badan Klinicznych PI-House sp. z o.o. — Gdansk, 80-546, Poland — Site recruitment status not specified in the registry data
Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET — Krakow, 31-261, Poland — Site recruitment status not specified in the registry data
Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna — Lodz, 90-338, Poland — Site recruitment status not specified in the registry data
Ekamed — Lublin, 20-718, Poland — Site recruitment status not specified in the registry data
Private Practice - Dr. Robert Witek — Tarnów, 33-100, Poland — Site recruitment status not specified in the registry data
NBR Polska — Warsaw, 00-710, Poland — Site recruitment status not specified in the registry data
Szpital Czerniakowski — Warsaw, 00-737, Poland — Site recruitment status not specified in the registry data
4 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ — Wroclaw, 50-981, Poland — Site recruitment status not specified in the registry data
Centro de Endocrinologia Alcantara Gonzalez — Bayamón, 00956, Puerto Rico — Site recruitment status not specified in the registry data
Mgcendo Llc — San Juan, 00921, Puerto Rico — Site recruitment status not specified in the registry data

Study details

Start date: March 28, 2025
Primary completion date: May 1, 2027
First posted: March 27, 2025

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT06897475
Registry last updated: September 14, 2026
QualifiedStudies registry data refreshed: September 21, 2026

View NCT06897475 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Diabetes (Type II) studies | Clinical trial FAQ